SEARCH:   Advanced

Blood, 15 February 2008, Vol. 111, No. 4, pp. 2152-2154. Prepublished online as a Blood First Edition Paper on November 28, 2007; DOI 10.1182/blood-2007-10-116111. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-10-116111v1 111/4/2152    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lob, S. Articles by Terness, P. Search for Related Content PubMed PubMed Citation Articles by Lob, S. Articles by Terness, P. Related Collections Immunobiology Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief Report Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells Stefan Lob1,2, Alfred Konigsrainer1, Richard Schafer3, Hans-Georg Rammensee2, Gerhard Opelz4, and Peter Terness4 1 Department of General, Visceral and Transplant Surgery, University Hospital of Tubingen, Tubingen; 2 Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tubingen, Tubingen; 3 Institute of Clinical and Experimental Transfusion Medicine, Eberhard Karls University of Tubingen, Tubingen; and 4 Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany Clinical trials have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). Here we show that human dendritic cells (DCs) express both IDO-1 and IDO-2, but that only IDO1 mediates tryptophan catabolism; furthermore, its activity is blocked by levo-1MT, whereas D-1MT is inefficient. Consequently, in humans any possible antitumor effects of D-1MT cannot be attributed to abrogation of IDO activity in DCs as described in this study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Qian, J. Villella, P. K. Wallace, P. Mhawech-Fauceglia, J. D. Tario Jr., C. Andrews, J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, et al. Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer Cancer Res., July 1, 2009; 69(13): 5498 - 5504. [Abstract] [Full Text] [PDF] H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF] A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood, March 12, 2009; 113(11): 2394 - 2401. [Abstract] [Full Text] [PDF] J. C. O'Connor, M. A. Lawson, C. Andre, E. M. Briley, S. S. Szegedi, J. Lestage, N. Castanon, M. Herkenham, R. Dantzer, and K. W. Kelley Induction of IDO by Bacille Calmette-Guerin Is Responsible for Development of Murine Depressive-Like Behavior J. Immunol., March 1, 2009; 182(5): 3202 - 3212. [Abstract] [Full Text] [PDF] M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA Clin. Cancer Res., January 15, 2009; 15(2): 641 - 649. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020